BOC Sciences社 2020-1 Monthly Featured Products Have Been Updated
2020-1 monthly featured products have been updated. BOC Sciences is a professional chemical supplier devoted to providing customers with superior and high-purity featured products, which are ready to be ordered from stock.
167 chemical products are recommended in this batch. Those products are under the API, Inhibitor, Impurity, Metabolite, ADC, Pharmaceutical Excipient, Natural Compound, Nucleoside, Probe, and Building Block categories.
89 featured APIs & inhibitors are provided in this batch. Tiaramide hydrochloride (B2692-018999) and Budesonide (B2692-070120) are two anti-inflammatory and analgesic drugs that both can be used as anti-asthmatic agents. Tiaramide is marketed under the trade name Solantol in Japan for the treatment of various pain and inflammatory disorders. Budesonide is a corticosteroid drug that attenuates symptoms of asthma by preventing inflammation (swelling) in the lungs. Fluorometholone acetate (B2692-393472) is also a corticosteroid drug with anti-inflammatory effects, used in ophthalmology. Fluorometholone acetate is formulated as an ophthalmic suspension called Flarex, which is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.
VEGFR signaling modulates angiogenesis, and is responsible for forming of new blood vessels from existing blood vessels, which plays key roles in tumorigenesis. VEGFR inhibitors are agents used for anticancer therapeutics in clinical trials. The VEGFR inhibitors we provide in this batch are: Regorafenib monohydrate (B2693-463493), Cabozantinib S-malate (B2693-457054), BMS-794833 (B2693-286366), Fruquintinib (B2693-470819), Apatinib (B2693-457664), Altiratinib (B2693-463181), SU5408 (B2693-312027), SU5402 (B2693-087527), PD173074 (B2693-263525), Cediranib dihydrochloride (B2693-065171), Oglufanide (B2693-114382), Vandetanib (B2693-344311), Pazopanib (B2693-068950), Tivozanib (B2693-413727), Quarfloxin (B2693-153274), Pazopanib HCl (B2693-146188), Brivanib alaninate (B2693-146708), Golvatinib (B2693-460626), ENMD-2076 (B2693-156198), Regorafenib Hydrochloride (B2693-459775), foretinib (B2693-152657), Cabozantinib (B2693-307706), Cediranib maleate (B2693-459903). Study has shown that the VEGFR inhibitors acts via binding juxtamembrane conformations of VEGFR kinase, blocking the interaction of VEGF and receptors. In addition to the products described above, more APIs and inhibitors are available for your projects.
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。